Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Large Decrease in Short Interest

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) saw a large drop in short interest in the month of October. As of October 15th, there was short interest totaling 173,200 shares, a drop of 34.5% from the September 30th total of 264,400 shares. Approximately 0.8% of the company’s shares are sold short. Based on an average daily trading volume, of 553,300 shares, the short-interest ratio is currently 0.3 days. Based on an average daily trading volume, of 553,300 shares, the short-interest ratio is currently 0.3 days. Approximately 0.8% of the company’s shares are sold short.

Hedge Funds Weigh In On Enlivex Therapeutics

A hedge fund recently raised its stake in Enlivex Therapeutics stock. Jane Street Group LLC raised its holdings in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) by 527.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 80,759 shares of the company’s stock after purchasing an additional 67,886 shares during the quarter. Jane Street Group LLC owned 0.34% of Enlivex Therapeutics worth $78,000 as of its most recent SEC filing. 1.02% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on ENLV shares. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Enlivex Therapeutics in a research note on Tuesday, September 2nd. D. Boral Capital reaffirmed a “buy” rating and set a $13.00 price objective on shares of Enlivex Therapeutics in a research note on Wednesday, October 29th. Wall Street Zen raised Enlivex Therapeutics to a “sell” rating in a research note on Saturday, August 30th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Enlivex Therapeutics in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $10.00.

Enlivex Therapeutics Stock Performance

Shares of NASDAQ ENLV traded down $0.01 during trading hours on Tuesday, reaching $1.04. 32,638 shares of the stock were exchanged, compared to its average volume of 242,506. The firm has a market capitalization of $25.26 million, a price-to-earnings ratio of -1.79 and a beta of 0.90. Enlivex Therapeutics has a 52 week low of $0.81 and a 52 week high of $2.10. The stock’s fifty day simple moving average is $1.07 and its 200 day simple moving average is $1.11.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.